Piper Sandler analyst Joseph Catanzaro raised the firm’s price target on Biomea Fusion (BMEA) to $19 from $10 and keeps an Overweight rating on the shares. The firm notes Biomea reported Q3 earnings and provided a pipeline update. Most notably, Biomea is now specifically guiding towards Phase II topline readouts in both T2D and T1D in December.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMEA: